Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Amgen’s (AMGN - Analyst Report) PCSK9 inhibitor, evolocumab (AMG 145), is one of the most promising and interesting candidates in the company’s pipeline. Evolocumab works by inhibiting PCSK9, a protein that reduces the liver's ability to remove "bad" cholesterol from the blood.

Amgen recently presented new data on evolocumab from an open-label extension study. Results from the long-term controlled 52-week safety and efficacy Open Label Study of Long TERm Evaluation Against LDL-C (OSLER), showed that monthly treatment with evolocumab was not associated with a major increase in adverse events (AEs) compared to standard of care (SOC). Moreover, mean LDL-C reductions of 52% were observed in high cholesterol patients receiving evolocumab plus SOC.

The results are encouraging and indicate that evolocumab could be a promising treatment option for hyperlipidemia in at-risk patients. These results were presented at the American Heart Association (AHA) Scientific Sessions 2013 and published in Circulation as well.

Amgen is conducting four pivotal phase III studies with evolocumab. Results are expected in the first quarter of 2014. We believe evolocumab has huge market potential. Other companies developing PSCK9 inhibitors include Sanofi (SNY - Analyst Report) and Pfizer (PFE - Analyst Report) among others.

Meanwhile, Amgen presented encouraging data on another pipeline candidate, talimogene laherparepvec, which is being studied in patients with unresected stage IIIB, IIIC or IV melanoma. Interim data from a phase III study comparing talimogene laherparepvec to granulocyte-macrophage colony-stimulating factor (GM-CSF) showed that median overall survival (OS) was higher in the talimogene laherparepvec arm (23.3 months versus 19.0 months). Mature OS data should be out in the first half of 2014.

Amgen currently carries a Zacks Rank #2 (Buy). Other companies that look well-positioned include Vanda Pharmaceuticals, Inc. (VNDA - Snapshot Report), a Zacks Rank #1 (Strong Buy) stock.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +6.05%
QUESTCOR PHA QCOR 80.07 +2.47%
VIPSHOP HOLD VIPS 156.35 +1.82%
ENLINK MIDST ENLC 36.29 +1.60%
BNC BANCORP BNCN 17.33 +1.58%